



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Cintirorgon

Cat. No.:	HY-104037
CAS No.:	2055536-64-4
Molecular Formula:	C ₂₇ H ₂₃ F ₆ NO ₆ S
Molecular Weight:	603.53
Target:	ROR
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 113.3 mg/mL (187.73 mM)
 Ethanol : 100 mg/mL (165.69 mM; Need ultrasonic)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.6569 mL	8.2846 mL	16.5692 mL
	5 mM		0.3314 mL	1.6569 mL	3.3138 mL
	10 mM		0.1657 mL	0.8285 mL	1.6569 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
 Solubility: ≥ 2.5 mg/mL (4.14 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable ROR γ agonist. Cintirorgon (LYC-55716) modulates gene expression of ROR γ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival^{[1][2]}.

IC₅₀ & Target

ROR γ ^[1]

In Vivo

Upon oral administration of ROR γ agonist Cintirorgon (LYC-55716), this agent selectively binds to the nuclear receptor transcription factor ROR γ , forming a receptor complex that translocates to the nucleus, and binds to ROR response elements (ROREs), enhancing the function, proliferation and survival of type 17 T cells, including Th17 (helper T cells) and Tc17 (cytotoxic T cells). ROR γ , the nuclear receptor transcription factor that is involved in Th17/Tc17 differentiation, plays a

key role in immune activation. Cintirorgon (LYC-55716) is also orally bioavailable, while the new generation of immuno-oncology drugs-ncluding PD-1/PD-L1 inhibitors are delivered by injection^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Pharmacol Res. 2021 Jul 30;105793.
- Diabetes. 2023 Aug 8;db220605.
- Antiviral Res. 2023 Dec 4:105769.
- Eur J Med Chem. 2021, 113585.
- Heliyon. 2023 Jun 28.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors. Jan 04, 2017.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA